Health Condition 1: K582- Mixed irritable bowel syndrome
Conditions
Interventions
Intervention1: Jirakadyarishta: Jirakadyarishta is a classical Ayurvedic medicines referred in API Part II Vol II PAGE 29-30 (YEAR OF PUBLICATION -2008),Dept of AYUSH,Govt. of India
Jirakadyarishta:
D
Dosage form : Arishta
Route of Administration : Oral
Time of Administration : Twice a day after food
Anupana (adjuvants) : Water
Duration of therapy : 12 weeks
Control Intervention1: Not applicable: Nil
Sponsors
Central Council for Research in Ayurvedic Sciences CCRAS New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of either sex aged 18-65 years 2. Known cases of Grahani (diagnostic criteria as per classical Ayurvedic parameters) a) Chronic or recurrent abdominal discomfort or pain b) Abdominal bloating c) Constipation d) Diarrhoea e) Urgency of bowel movements f) Feeling of incomplete evacuation g) Passage of mucus 3. Patients willing to give written informed consent and able to participate for 3 months.
Exclusion criteria
Exclusion criteria: 1. Patients with history of Inflammatory Bowel Disease (IBD), Kochââ?¬•s abdomen, Gluten intolerance. 2. Patients with history of chronic Amoebiasis. 3. Known cases of Diabetes Mellitus. 4. Patients with poorly controlled Hypertension ( >160/100 mmHg) 5. Patients who have history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months 6. Symptomatic patients with clinical evidence of Heart failure 7. Known cases of malignancy 8. Patients with concurrent serious hepatic disorders (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT) > 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease (COPD). 9. Women who are planning for conception / pregnant or lactating. 10. H/o hypersensitivity to any of the trial drugs or their ingredients 11. Patients who have completed participation in any other clinical trial during the past three months 12. Any other condition which the Investigator thinks may jeopardize the study
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| To assess the clinical efficacy of Jirakadyarishta by the assessment of Changes in IBS-QOL scoreTimepoint: at the end of 14th day, 28th day, 42nd day, 56th day, 70th day, 84th day and 98th day | — |
Primary
| Measure | Time frame |
|---|---|
| To assess the clinical efficacy of Jirakadyarishta by the assessment of Changes in Ayurvedic Parameters of GrahaniTimepoint: at the end of14th day, 28th day, 42nd day, 56th day, 70th day, 84th day and 98th day | — |
Countries
India
Contacts
Public ContactDr Kshirod Kumar Ratha
Central Ayurveda Research Institute For Hepatobiliary Disorders, Bhubaneswar
Outcome results
None listed